Kriya Therapeutics, a gene therapy company advancing a broad portfolio of therapeutics, has appointed Curt Herberts, M.B.S., as President and Chief Operating Officer.
Herberts will oversee all general and administrative functions at Kriya.
Herberts joins Kriya from Senti Biosciences, Inc., where he was Chief Financial Officer and Chief Business Officer from 2018 to 2021, and Chief Operating Officer from 2021 to 2022. Prior to joining Senti, Herberts held various positions at Sangamo Therapeutics including as the company’s Chief Business Officer, as well as at Campbell Alliance Group, a leading management consulting firm specializing in the life science industry. Herberts earned his B.A. from Stanford University in human biology, and his Master of Business and Science from the Keck Graduate Institute of Applied Life Sciences.
With core operations in Silicon Valley, California and Research Triangle Park, North Carolina; Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy. The company aims to revolutionize how gene therapies are designed, developed, and manufactured, improving speed to market and delivering significant reductions in cost. The company’s current pipeline includes programs in ophthalmology, oncology, rare disease, and chronic disease.